{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:08:35Z","timestamp":1792177715100,"version":"4.4.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The pharmacological management of hyperkalemia traditionally considered calcium or sodium polystyrene sulfonate and, since recently, the novel binders patiromer and sodium zirconium cyclosilicate. We evaluated their patterns of use, duration of treatment and relative effectiveness\/safety in Swedish routine care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Observational study of adults initiating therapy with sodium polystyrene sulfonate or a novel binder (sodium zirconium cyclosilicate or patiromer) in Stockholm 2019\u20132021. We quantified treatment duration by repeated dispensations, compared mean achieved potassium concentration within 60\u00a0days, and potential adverse events between treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 1879 adults started treatment with sodium polystyrene sulfonate, and 147 with novel binders (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200941 patiromer and\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009106 sodium zirconium cyclosilicate). Potassium at baseline for all treatments was 5.7\u00a0mmol\/L. Sodium polystyrene sulfonate patients stayed on treatment a mean of 61\u00a0days (14% filled \u22653 consecutive prescriptions) compared to 109\u00a0days on treatment (49% filled \u22653 prescriptions) for novel binders. After 15\u00a0days of treatment, potassium similarly decreased to 4.6 (SD 0.6) and 4.8 (SD 0.6) mmol\/L in the sodium polystyrene sulfonate and novel binder groups, respectively, and was maintained over the 60\u00a0days post-treatment. In multivariable regression, the odds ratio for novel binders (vs sodium polystyrene sulfonate) in reaching potassium\u2009\u2264\u20095.0\u00a0mmol\/L after 15\u00a0days was 0.65 (95% CI 0.38\u20131.10) and after 60\u00a0days 0.89 (95% CI 0.45\u20131.76). Hypocalcemia, hypokalemia, and initiation of anti-diarrheal\/constipation medications were the most-commonly detected adverse events. In multivariable analyses, the OR for these events did not differ between groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We observed similar short-term effectiveness and safety for all potassium binders. However, treatment duration was longer for novel binders than for sodium polystyrene sulfonate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s40620-023-01860-0","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T06:40:10Z","timestamp":1705560010000},"page":"961-972","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Evaluation of the introduction of novel potassium binders in routine care; the Stockholm CREAtinine measurements (SCREAM) project"],"prefix":"10.1093","volume":"37","author":[{"given":"Ailema","family":"Gonzalez-Ortiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Clase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Bosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edouard L.","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz E.","family":"P\u00e9rez-Guill\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Faucon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Zoccali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4763-2024","authenticated-orcid":false,"given":"Juan-Jes\u00fas","family":"Carrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,18]]},"reference":[{"issue":"3","key":"1860_CR1","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.mayocp.2020.06.014","volume":"96","author":"BF Palmer","year":"2021","unstructured":"Palmer BF et al (2021) Clinical Management of Hyperkalemia. Mayo Clin Proc 96(3):744\u2013762","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"1860_CR2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.kint.2019.09.018","volume":"97","author":"CM Clase","year":"2020","unstructured":"Clase CM et al (2020) Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 97(1):42\u201361","journal-title":"Kidney Int"},{"issue":"10208","key":"1860_CR3","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","volume":"394","author":"R Agarwal","year":"2019","unstructured":"Agarwal R et al (2019) Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 394(10208):1540\u20131550","journal-title":"Lancet"},{"key":"1860_CR4","unstructured":"Butler J et al. (2022) Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. Eur Heart J"},{"issue":"6","key":"1860_CR5","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1038\/ki.2015.270","volume":"88","author":"DA Bushinsky","year":"2015","unstructured":"Bushinsky DA et al (2015) Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia. Kidney Int 88(6):1427\u20131433","journal-title":"Kidney Int"},{"issue":"3","key":"1860_CR6","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1410853","volume":"372","author":"MR Weir","year":"2015","unstructured":"Weir MR et al (2015) Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 372(3):211\u2013221","journal-title":"N Engl J Med"},{"issue":"2","key":"1860_CR7","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1001\/jama.2015.7446","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris GL et al (2015) Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA 314(2):151\u2013161","journal-title":"JAMA"},{"issue":"1","key":"1860_CR8","first-page":"54","volume":"7","author":"F Zannad","year":"2020","unstructured":"Zannad F et al (2020) Efficacy and safety of sodium zirconium cyclosilicate for hyperkalaemia: the randomized, placebo-controlled HARMONIZE-Global study. ESC Heart Fail 7(1):54\u201364","journal-title":"ESC Heart Fail"},{"issue":"12","key":"1860_CR9","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.2215\/CJN.03640415","volume":"10","author":"L Lepage","year":"2015","unstructured":"Lepage L et al (2015) Randomized clinical trial of sodium polystyrene sulfonate for the treatment of mild hyperkalemia in CKD. Clin J Am Soc Nephrol 10(12):2136\u20132142","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"1860_CR10","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1093\/ckj\/sfac129","volume":"15","author":"DA Jaques","year":"2022","unstructured":"Jaques DA et al (2022) Comparative efficacy of patiromer and sodium polystyrene sulfonate on potassium levels in chronic haemodialysis patients: a randomized crossover trial. Clin Kidney J 15(10):1908\u20131914","journal-title":"Clin Kidney J"},{"issue":"6","key":"1860_CR11","doi-asserted-by":"publisher","first-page":"798","DOI":"10.2215\/CJN.12651018","volume":"14","author":"BS Spinowitz","year":"2019","unstructured":"Spinowitz BS et al (2019) Sodium zirconium cyclosilicate among individuals with hyperkalemia: a 12-month phase 3 study. Clin J Am Soc Nephrol 14(6):798\u2013809","journal-title":"Clin J Am Soc Nephrol"},{"key":"1860_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2022.175174","volume":"931","author":"L Dong","year":"2022","unstructured":"Dong L et al (2022) Efficacy and safety of potassium binders in the treatment of patients with chronic kidney disease and hyperkalemia. Eur J Pharmacol 931:175174","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"1860_CR13","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1093\/ckj\/sfac209","volume":"16","author":"R Pecoits-Filho","year":"2023","unstructured":"Pecoits-Filho R et al (2023) Patiromer utilization in patients with advanced chronic kidney disease under nephrology care in Germany. Clin Kidney J 16(1):176\u2013183","journal-title":"Clin Kidney J"},{"issue":"50","key":"1860_CR14","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000032367","volume":"101","author":"D Pinnell","year":"2022","unstructured":"Pinnell D et al (2022) Real-world evaluation of patiromer utilization and its effects on serum potassium in veterans with end stage kidney disease. Medicine (Baltimore) 101(50):e32367","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"1860_CR15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.45236","volume":"5","author":"KE Di Palo","year":"2022","unstructured":"Di Palo KE, Sinnett MJ, Goriacko P (2022) Assessment of patiromer monotherapy for hyperkalemia in an acute care setting. JAMA Netw Open 5(1):e2145236","journal-title":"JAMA Netw Open"},{"issue":"2","key":"1860_CR16","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1080\/00325481.2019.1706920","volume":"132","author":"CP Kovesdy","year":"2020","unstructured":"Kovesdy CP et al (2020) Real-world management of hyperkalemia with patiromer among United States Veterans. Postgrad Med 132(2):176\u2013183","journal-title":"Postgrad Med"},{"key":"1860_CR17","doi-asserted-by":"publisher","first-page":"1137981","DOI":"10.3389\/fmed.2023.1137981","volume":"10","author":"T Nakayama","year":"2023","unstructured":"Nakayama T et al (2023) Compared effectiveness of sodium zirconium cyclosilicate and calcium polystyrene sulfonate on hyperkalemia in patients with chronic kidney disease. Front Med 10:1137981","journal-title":"Front Med"},{"issue":"12","key":"1860_CR18","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1111\/jcpt.13766","volume":"47","author":"AB Huda","year":"2022","unstructured":"Huda AB et al (2022) Hyperkalaemia and potassium binders: retrospective observational analysis looking at the efficacy and cost effectiveness of calcium polystyrene sulfonate and sodium zirconium cyclosilicate. J Clin Pharm Ther 47(12):2170\u20132175","journal-title":"J Clin Pharm Ther"},{"issue":"9","key":"1860_CR19","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000033134","volume":"102","author":"S Patel","year":"2023","unstructured":"Patel S et al (2023) Assessing patiromer utilization and associated serum potassium changes in US veterans with prior sodium polystyrene sulfonate exposure. Medicine (Baltimore) 102(9):e33134","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"1860_CR20","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ekir.2018.10.020","volume":"4","author":"CP Kovesdy","year":"2019","unstructured":"Kovesdy CP et al (2019) Real-world evaluation of patiromer for the treatment of hyperkalemia in hemodialysis patients. Kidney Int Rep 4(2):301\u2013309","journal-title":"Kidney Int Rep"},{"issue":"9","key":"1860_CR21","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/j.cardfail.2022.04.003","volume":"28","author":"M Zhuo","year":"2022","unstructured":"Zhuo M et al (2022) Risk of hospitalization for heart failure in patients with hyperkalemia treated with sodium zirconium cyclosilicate versus patiromer. J Card Fail 28(9):1414\u20131423","journal-title":"J Card Fail"},{"issue":"3","key":"1860_CR22","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/joim.13418","volume":"291","author":"JJ Carrero","year":"2022","unstructured":"Carrero JJ, Elinder CG (2022) The Stockholm CREAtinine measurements (SCREAM) project: fostering improvements in chronic kidney disease care. J Intern Med 291(3):254\u2013268","journal-title":"J Intern Med"},{"issue":"9","key":"1860_CR23","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1093\/ndt\/gfz150","volume":"35","author":"P Laureati","year":"2020","unstructured":"Laureati P et al (2020) Initiation of sodium polystyrene sulphonate and the risk of gastrointestinal adverse events in advanced chronic kidney disease: a nationwide study. Nephrol Dial Transplant 35(9):1518\u20131526","journal-title":"Nephrol Dial Transplant"},{"key":"1860_CR24","unstructured":"https:\/\/www.fass.se\/LIF\/atcregister?userType=0&atcCode 08 march 2023]."},{"issue":"9","key":"1860_CR25","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604\u2013612","journal-title":"Ann Intern Med"},{"key":"1860_CR26","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney inter., Suppl. 2013; 3: 1\u2013150."},{"issue":"1","key":"1860_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/eurjpc\/zwab154","volume":"29","author":"FLJ Visseren","year":"2022","unstructured":"Visseren FLJ et al (2022) 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur J Prev Cardiol 29(1):5\u2013115","journal-title":"Eur J Prev Cardiol"},{"issue":"3","key":"1860_CR28","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.cjca.2015.06.019","volume":"32","author":"JG Howlett","year":"2016","unstructured":"Howlett JG et al (2016) The canadian cardiovascular society heart failure companion: bridging guidelines to your practice. Can J Cardiol 32(3):296\u2013310","journal-title":"Can J Cardiol"},{"issue":"9","key":"1860_CR29","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000001037","volume":"6","author":"K Schnelle","year":"2020","unstructured":"Schnelle K et al (2020) Largest experience of safety and efficacy of patiromer in solid organ transplant. Transplant Direct 6(9):e595","journal-title":"Transplant Direct"},{"key":"1860_CR30","doi-asserted-by":"crossref","unstructured":"Haller H et al. (2022) Safety and efficacy of patiromer in hyperkalemic patients with CKD: a pooled analysis of three randomized trials. kidney 360, 3(12): 2019\u20132026.","DOI":"10.34067\/KID.0001562022"},{"key":"1860_CR31","doi-asserted-by":"crossref","unstructured":"Scicchitano P et al. Optimizing Therapies in Heart Failure: The Role of Potassium Binders. Biomedicines, 2022. 10(7).","DOI":"10.3390\/biomedicines10071721"},{"issue":"7","key":"1860_CR32","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","volume":"32","author":"B Pitt","year":"2011","unstructured":"Pitt B et al (2011) Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J 32(7):820\u2013828","journal-title":"Eur Heart J"},{"issue":"1","key":"1860_CR33","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12882-023-03145-x","volume":"24","author":"AE Ca\u00f1as","year":"2023","unstructured":"Ca\u00f1as AE et al (2023) A randomized study to compare oral potassium binders in the treatment of acute hyperkalemia. BMC Nephrol 24(1):89","journal-title":"BMC Nephrol"},{"issue":"4","key":"1860_CR34","first-page":"455","volume":"26","author":"K Nasir","year":"2014","unstructured":"Nasir K, Ahmad A (2014) Treatment of hyperkalemia in patients with chronic kidney disease: a comparison of calcium polystyrene sulphonate and sodium polystyrene sulphonate. J Ayub Med Coll Abbottabad 26(4):455\u2013458","journal-title":"J Ayub Med Coll Abbottabad"},{"key":"1860_CR35","unstructured":"http:\/\/fda.com\/. 2023\u201302\u201320]."},{"issue":"5","key":"1860_CR36","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1093\/ckj\/sfaa244","volume":"14","author":"M Trevisan","year":"2021","unstructured":"Trevisan M et al (2021) Pharmacoepidemiology for nephrologists (part 1): concept, applications and considerations for study design. Clin Kidney J 14(5):1307\u20131316","journal-title":"Clin Kidney J"},{"issue":"5","key":"1860_CR37","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1093\/ckj\/sfaa242","volume":"14","author":"EL Fu","year":"2021","unstructured":"Fu EL et al (2021) Pharmacoepidemiology for nephrologists (part 2): potential biases and how to overcome them. Clin Kidney J 14(5):1317\u20131326","journal-title":"Clin Kidney J"},{"issue":"8","key":"1860_CR38","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1001\/jamainternmed.2019.0631","volume":"179","author":"JA Noel","year":"2019","unstructured":"Noel JA et al (2019) Risk of hospitalization for serious adverse gastrointestinal events associated with sodium polystyrene sulfonate use in patients of advanced age. JAMA Intern Med 179(8):1025\u20131033","journal-title":"JAMA Intern Med"},{"issue":"2","key":"1860_CR39","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/ndt\/gfaa229","volume":"36","author":"JP Ferreira","year":"2021","unstructured":"Ferreira JP et al (2021) Adverse gastrointestinal events with sodium polystyrene sulphonate and calcium polystyrene sulphonate use in dialysis patients: a nationwide registry study. Nephrol Dial Transplant 36(2):339\u2013345","journal-title":"Nephrol Dial Transplant"},{"key":"1860_CR40","doi-asserted-by":"crossref","unstructured":"Carrero JJ et al. Pharmacological strategies to manage hyperkalemia: out with the old, in with the new? Not so fast\u2026. Clinical Kidney Journal, 2023.","DOI":"10.1093\/ckj\/sfad089"},{"issue":"1","key":"1860_CR41","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s12882-022-02903-7","volume":"23","author":"K Kim","year":"2022","unstructured":"Kim K et al (2022) Cost effectiveness of sodium zirconium cyclosilicate for the treatment of hyperkalaemia in patients with CKD in Norway and Sweden. BMC Nephrol 23(1):281","journal-title":"BMC Nephrol"},{"issue":"41","key":"1860_CR42","doi-asserted-by":"publisher","first-page":"4362","DOI":"10.1093\/eurheartj\/ehac401","volume":"43","author":"J Butler","year":"2022","unstructured":"Butler J et al (2022) Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. Eur Heart J 43(41):4362\u20134373","journal-title":"Eur Heart J"},{"issue":"41","key":"1860_CR43","doi-asserted-by":"publisher","first-page":"4374","DOI":"10.1093\/eurheartj\/ehac399","volume":"43","author":"M Packer","year":"2022","unstructured":"Packer M (2022) Potassium binders for patients with heart failure? The real enlightenment of the DIAMOND. trial Euro Heart J 43(41):4374\u20134377","journal-title":"trial Euro Heart J"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-023-01860-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-023-01860-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-023-01860-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:58:45Z","timestamp":1777564725000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/37\/4\/961\/8384006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,18]]},"references-count":43,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["1860"],"URL":"https:\/\/doi.org\/10.1007\/s40620-023-01860-0","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,18]]},"assertion":[{"value":"5 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JJC has conducted studies for which Karolinska Institutet has received support from AstraZeneca (manufacturer of sodium zirconium cyclosilicate), ViforPharma (manufacturer of patiromer), Novonordisk, Astellas, MSD, GSK, Boehringer Ingelheim and Amgen; He also reports receiving lecture fees from Baxter, Fresenius Kabi, AstraZeneca, Astellas, GSK and Abbott; and participation in advisory boards for Astrazeneca, Nestle and Bayer; ME reports payment for lectures (Astellas pharma, Vifor pharma, Astra Zeneca, Baxter healthcare and Fresenius Medical care) and attendance in advisory boards (Astellas pharma, Vifor pharma, Astra Zeneca). The rest of the authors have no conflict of interest to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The regional ethical review board in Stockholm approved the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The present study complies with the guidelines for human studies.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"Informed consent was not deemed necessary because all data were deidentified at the Swedish Board of Health and Welfare.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}